OBX · Obsidian Therapeutics, Inc.
Market Cap
$1.06B
Shares
61.77M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$17.00
Open$17.35
Day$16.25–18.02
Available close range$15.57–35.00
Avg vol available · 25d130K
Short int36K · 0.1% float · 1.0d
Short vol49%
Last earningsAug 3, 2026
DataJul 2026–Sep 2026
Filing10-Q · Aug 14
The closing range uses available history since Jul 28, 2026; less than a full year is stored.
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$16.46M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+56.4%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.1%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Limited
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.47
Technical
price trend
50 / 200-day cross
No cross
RSI (14)
50
neutral
52-week position
7%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
Not enough data for a confident read.
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.06% of float · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Squeeze score
25
low risk · 0–100
Fundamentals
EPS growth
−12%
Y/Y
Free cash flow
$-90.5M
Quant / Vol
risk profile
Volatility
320%
annualized · 1-yr
Max drawdown
−53%
past year
ATR
25.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
RSI (14)
50
Neutral
52-week position
7%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.06% of float · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its available closing range
Range low $16
Now $17 · 7%
Range high $35
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OBX
this stock
Obsidian Therapeutics, Inc.
|
$1.06B | — | — | — | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$140.51B | +22.8% | +46.2% | 32.3 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.82B | +10.4% | +20.8% | 20.4 | 2.3% |
|
ARGX
Argenx SE
|
$65.63B | +25.5% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.96B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OBX | -7.6% | -40.4% | — | -2.9% | — |
| SPY | -0.1% | -0.6% | +14.9% | -0.3% | +12.2% |
| vs SPY | -7.5% | -39.8% | — | -2.7% | — |